Thus far, >20 LAG-3-targeting therapeutics are under clinical trials, and a fixed-dose combination of anti-LAG-3 and anti-PD-1 has been approved for unresectable or metastatic melanoma treatment (77). This evidence concerns the gene PDCD1 and metastatic melanoma.